Literature DB >> 11006643

[Prenatal corticosteroids. Use and attitudes of the gynecology-obstetrics medical staff].

A Vargas-Origel1, D León Ramírez, J Zamora-Orozco, M A Vargas-Nieto.   

Abstract

OBJECTIVES: 1. To evaluate the frequency of use of antenatal corticosteroids (AC) and the reasons for withholding them. 2. To estimate the knowledge and attitudes, regarding AC, from obstetricians, in a large Women and Babies Hospital.
METHODS: Through a prospective, observational and transversal study we evaluated: 1. The frequency of use of AC in pregnant with preterm labor (PL) and in mothers of preterm infants (P1). When AC were not given, the reasons were recorded. 2. With an anonymous inquiry we assessed the knowledge and attitude of obstetricians regarding AC, exploring different concepts such as usefulness, frequency of use, indications, risks and contraindications. Descriptive statistics was used.
RESULTS: We studied 364 patients (240 mothers of Pl and 124 pregnant women). The mean gestational age (GA) was 28.9 + 2.4 weeks. The AC were used only in 136 out of 364 (37.4%) women, and diminished to 30.9% (102/330), if are excluded 34 patients who did not receive AC because imminent delivery. Another reasons for not using AC were irregular uterine activity (18.9%), prolonged rupture of membranes without chorioamnioitis (11.4%), and GA lower than 27 weeks (11.4%) and toxemia (9.6%). Only in 43 out of 136 patients (31.6%) who were on tocolytic drugs, received AC. The schedule and doses were correct. According to the inquiry, 48/68 (0.71) of obstetricians considered AC as definitively useful, although only 22/68 (0.32) as very effective. The knowledge level was acceptable, except in signaling with precision the neonatal problems that could be prevented, as well as the lowest gestational age for use the AC.
CONCLUSIONS: We considered the use of AC in our institution as suboptimal. We found that the reasons for not using them were not valid in most cases. Physician's attitudes to AC are positive but it is not reflected on their clinical practice. It is necessary a strong promotion of the usefulness of the AC for the preterm infant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006643

Source DB:  PubMed          Journal:  Ginecol Obstet Mex        ISSN: 0300-9041


  7 in total

1.  Factors influencing appropriate use of interventions for management of women experiencing preterm birth: A mixed-methods systematic review and narrative synthesis.

Authors:  Rana Islamiah Zahroh; Alya Hazfiarini; Katherine E Eddy; Joshua P Vogel; Ӧzge Tunçalp; Nicole Minckas; Fernando Althabe; Olufemi T Oladapo; Meghan A Bohren
Journal:  PLoS Med       Date:  2022-08-23       Impact factor: 11.613

2.  Use of prenatal corticosteroids for preterm birth in three Latin American countries.

Authors:  Alicia Aleman Riganti; Maria Luisa Cafferata; Fernando Althabe; Luz Gibbons; Jose Ortiz Segarra; Xochitl Sandoval; José M Belizán
Journal:  Int J Gynaecol Obstet       Date:  2010-01       Impact factor: 3.561

3.  A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial.

Authors:  Fernando Althabe; José M Belizán; Elizabeth M McClure; Jennifer Hemingway-Foday; Mabel Berrueta; Agustina Mazzoni; Alvaro Ciganda; Shivaprasad S Goudar; Bhalachandra S Kodkany; Niranjana S Mahantshetti; Sangappa M Dhaded; Geetanjali M Katageri; Mrityunjay C Metgud; Anjali M Joshi; Mrutyunjaya B Bellad; Narayan V Honnungar; Richard J Derman; Sarah Saleem; Omrana Pasha; Sumera Ali; Farid Hasnain; Robert L Goldenberg; Fabian Esamai; Paul Nyongesa; Silas Ayunga; Edward A Liechty; Ana L Garces; Lester Figueroa; K Michael Hambidge; Nancy F Krebs; Archana Patel; Anjali Bhandarkar; Manjushri Waikar; Patricia L Hibberd; Elwyn Chomba; Waldemar A Carlo; Angel Mwiche; Melody Chiwila; Albert Manasyan; Sayury Pineda; Sreelatha Meleth; Vanessa Thorsten; Kristen Stolka; Dennis D Wallace; Marion Koso-Thomas; Alan H Jobe; Pierre M Buekens
Journal:  Lancet       Date:  2014-10-15       Impact factor: 79.321

4.  Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries: study protocol.

Authors:  Fernando Althabe; José M Belizán; Agustina Mazzoni; Mabel Berrueta; Jay Hemingway-Foday; Marion Koso-Thomas; Elizabeth McClure; Elwyn Chomba; Ana Garces; Shivaprasad Goudar; Bhalchandra Kodkany; Sarah Saleem; Omrana Pasha; Archana Patel; Fabian Esamai; Waldemar A Carlo; Nancy F Krebs; Richard J Derman; Robert L Goldenberg; Patricia Hibberd; Edward A Liechty; Linda L Wright; Eduardo F Bergel; Alan H Jobe; Pierre Buekens
Journal:  Reprod Health       Date:  2012-09-19       Impact factor: 3.223

Review 5.  Born too soon: care during pregnancy and childbirth to reduce preterm deliveries and improve health outcomes of the preterm baby.

Authors:  Jennifer Requejo; Mario Merialdi; Fernando Althabe; Matthais Keller; Joanne Katz; Ramkumar Menon
Journal:  Reprod Health       Date:  2013-11-25       Impact factor: 3.223

6.  The Antenatal Corticosteroids Trial (ACT)'s explanations for neonatal mortality - a secondary analysis.

Authors:  Fernando Althabe; Vanessa Thorsten; Karen Klein; Elizabeth M McClure; Patricia L Hibberd; Robert L Goldenberg; Waldemar A Carlo; Ana Garces; Archana Patel; Omrana Pasha; Elwyn Chomba; Nancy F Krebs; Shivaprasad Goudar; Richard J Derman; Fabian Esamai; Edward A Liechty; Nellie I Hansen; Sreelatha Meleth; Dennis D Wallace; Marion Koso-Thomas; Alan H Jobe; Pierre M Buekens; José M Belizán
Journal:  Reprod Health       Date:  2016-05-24       Impact factor: 3.223

7.  The Antenatal Corticosteroids Trial (ACT): a secondary analysis to explore site differences in a multi-country trial.

Authors:  Karen Klein; Elizabeth M McClure; Daniela Colaci; Vanessa Thorsten; Patricia L Hibberd; Fabian Esamai; Ana Garces; Archana Patel; Sarah Saleem; Omrana Pasha; Elwyn Chomba; Waldemar A Carlo; Nancy F Krebs; Shivaprasad Goudar; Richard J Derman; Edward A Liechty; Marion Koso-Thomas; Pierre M Buekens; José M Belizán; Robert L Goldenberg; Fernando Althabe
Journal:  Reprod Health       Date:  2016-05-24       Impact factor: 3.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.